[Clinical studies on cefadroxil in pediatrics (author's transl)].
The present paper reports the results which were obtained in a clinical trial of cefadroxil (CDX), a new oral cephalosporin, in the pediatric field. (1) A total of 20 patients with infectious diseases including 9 urinary tract infection, 7 acute tonsillitis, 2 scarlet fever, 1 pyodermia and 1 recurrent bronchitis were treated with CDX. Of the 20 cases, the clinical response was excellent in 15 cases (75%), good in 4 cases (20%), and fair in 1 case (5%). (2) Efficacy classified by causative organisms was as follows; E. coli, 100%; S. pyogenes, 87.5%. (3) Neither adverse reactions nor abnormal laboratory results were observed.
D000293:Adolescent; D000367:Age Factors; D001419:Bacteria / Q000187:drug effects; D001424:Bacterial Infections / Q000188:drug therapy* / Q000382:microbiology; D002434:Cefadroxil; D002506:Cephalexin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000494:pharmacology; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D004352:Drug Resistance, Microbial; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male
D002434:Cefadroxil; D002506:Cephalexin